J
Jeffrey D. Whitman
Researcher at University of California, San Francisco
Publications - 30
Citations - 1445
Jeffrey D. Whitman is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Chagas disease. The author has an hindex of 12, co-authored 23 publications receiving 929 citations. Previous affiliations of Jeffrey D. Whitman include University of California, Berkeley.
Papers
More filters
Posted ContentDOI
Test performance evaluation of SARS-CoV-2 serological assays
TL;DR: Informed use of serology will require evaluations covering the full spectrum of SARS-CoV-2 infections, from asymptomatic and mild infection to severe disease, and later convalescence, to guide rational clinical and public health policies.
Journal ArticleDOI
Evaluation of SARS-CoV-2 serology assays reveals a range of test performance.
Jeffrey D. Whitman,Joseph Hiatt,Cody T. Mowery,Brian R. Shy,Ruby Yu,Tori N. Yamamoto,Ujjwal Rathore,Gregory M. Goldgof,Caroline Whitty,Jonathan M. Woo,Jonathan M. Woo,Antonia E. Gallman,Tyler E. Miller,Andrew G. Levine,David N. Nguyen,David N. Nguyen,Sagar P. Bapat,Joanna Balcerek,Sophia A. Bylsma,Ana M. Lyons,Stacy Li,Allison W. Wong,Eva M. Gillis-Buck,Zachary Steinhart,Youjin Lee,Ryan Apathy,Ryan Apathy,Mitchell J. Lipke,Jennifer A Smith,Tina Zheng,Ian C. Boothby,Erin Isaza,Jackie Chan,Dante D. Acenas,Jinwoo Lee,Trisha A. Macrae,Than S. Kyaw,David Wu,Dianna Ng,Wei Gu,Vanessa A. York,Haig A. Eskandarian,Perri C. Callaway,Perri C. Callaway,Lakshmi Warrier,Mary E. Moreno,Justine Levan,Leonel Torres,Lila A. Farrington,Rita P. Loudermilk,Kanishka Koshal,Kelsey C. Zorn,Wilfredo F. Garcia-Beltran,Diane Yang,Michael G Astudillo,Bradley E. Bernstein,Jeffrey A. Gelfand,Edward T. Ryan,Richelle C. Charles,A. John Iafrate,Jochen K. Lennerz,Steve Miller,Charles Y. Chiu,Susan L. Stramer,Michael R. Wilson,Aashish Manglik,Chun Jimmie Ye,Nevan J. Krogan,Nevan J. Krogan,Mark S. Anderson,Jason G. Cyster,Joel D. Ernst,Alan H.B. Wu,Kara L. Lynch,Caryn Bern,Patrick D. Hsu,Alexander Marson +76 more
TL;DR: A head-to-head evaluation of ten point-of-care-style lateral flow assays and two laboratory-based enzyme-linked immunosorbent assays to detect anti-SARS-CoV-2 IgM and IgG antibodies in 5-d time intervals from symptom onset underline the importance of seropositivity threshold determination and reader training for reliable LFA deployment.
Journal ArticleDOI
Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity
Kara L. Lynch,Jeffrey D. Whitman,Noreen P Lacanienta,Erica W Beckerdite,Shannon A Kastner,Brian R. Shy,Gregory M. Goldgof,Andrew G. Levine,Sagar P. Bapat,Susan L. Stramer,Jonathan H. Esensten,Allen W. Hightower,Caryn Bern,Alan Hb Wu +13 more
TL;DR: High sensitivity assays with a robust dynamic range provide a comprehensive picture of host antibody response to SARS-CoV-2, and IgM and IgG responses were significantly higher in patients with severe than mild disease.
Journal ArticleDOI
Chagas Disease in the United States: a Public Health Approach.
TL;DR: Making progress will require efforts to improve awareness among providers and patients, data on diagnostic test performance and expanded availability of confirmatory testing, and evidence-based strategies to improve access to appropriate management of Chagas disease in the United States.
Journal ArticleDOI
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.
Dianna Ng,Gregory M. Goldgof,Brian R. Shy,Andrew G. Levine,Joanna Balcerek,Sagar P. Bapat,John Prostko,Mary A. Rodgers,Kelly E. Coller,Sandra Pearce,Sergej Franz,Li Du,Mars Stone,Satish K. Pillai,Alicia Sotomayor-Gonzalez,Venice Servellita,Claudia Sanchez San Martin,Andrea Granados,Dustin R. Glasner,Lucy M. Han,Kent Truong,Naomi Akagi,David N. Nguyen,Neil M. Neumann,Daniel Qazi,Elaine Hsu,Wei Gu,Yale A. Santos,Brian Custer,Valerie Green,Phillip C. Williamson,Nancy K. Hills,Chuanyi M. Lu,Jeffrey D. Whitman,Susan L. Stramer,Candace Wang,Kevin Reyes,Jill Hakim,Kirk Sujishi,Fariba Alazzeh,Lori Pham,Edward Thornborrow,Ching Ying Oon,Steve Miller,Theodore W. Kurtz,Graham Simmons,John Hackett,Michael P. Busch,Charles Y. Chiu +48 more
TL;DR: There is evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity, and the importance of using highly accurate tests for surveillance studies in low-prevalence populations is emphasized.